{"id":"W3009108936","doi":"10.3747/co.27.5933","title":"Systemic Adjuvant Therapy for Adult Patients at High Risk for Recurrent Cutaneous or Mucosal Melanoma: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline","year":2020,"lang":"en","type":"article","venue":"Current Oncology","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"Kingston General Hospital; Health Sciences Centre; Ottawa Hospital; University of Ottawa; Queen's University; Grand River Hospital; Juravinski Hospital; Cancer Care Ontario; McMaster University; Credit Valley Hospital; Juravinski Cancer Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Dabrafenib; Ipilimumab; Pembrolizumab; Nivolumab; Melanoma; Trametinib; Guideline; Internal medicine; Oncology; Cancer; Adjuvant therapy; Mucosal melanoma; Dermatology; Immunotherapy; Vemurafenib; Pathology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":true,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009070479,0.001031456,0.001728593,0.003283481,0.0015402,0.001935124,0.004200869,0.004806809,0.003928647],"category_scores_gemma":[0.0209402,0.000760393,0.0028565,0.004642936,0.001192891,0.001501867,0.001609456,0.003867135,0.001794029],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.01832888,"about_ca_system_score_gemma":0.07207707,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.3483274,"about_ca_topic_score_gemma":0.591889,"domain_scores_codex":[0.9929925,0.002039814,0.001980955,0.0003423715,0.002217196,0.0004271693],"domain_scores_gemma":[0.9808749,0.002330593,0.002989982,0.0002444313,0.01212831,0.001431829],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001015647,0.000144174,0.004003884,0.02069549,0.0003539437,0.0006187728,0.001054866,0.0007483001,0.0007567198,0.00250705,0.7966374,0.1723778],"study_design_scores_gemma":[0.0007390258,0.0001356999,0.02050496,0.06687266,0.001201264,0.000735639,0.0005405199,0.001087856,0.000277431,0.003048326,0.9047441,0.000112518],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"methods","genre_scores_codex":[0.006583215,0.3782207,0.0147868,0.4961942,0.007991104,0.01154245,0.0145469,0.0005596477,0.06957496],"genre_scores_gemma":[0.06598665,0.5267203,0.1894129,0.1318837,0.004940317,0.01591817,0.02802786,0.000166303,0.03694392],"genre_candidate":"methods","genre_consensus":null,"teacher_disagreement_score":0.6516726,"threshold_uncertainty_score":0.6925998,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1120385506817287,"score_gpt":0.4392480465217246,"score_spread":0.3272094958399958,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}